Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China

摘要

Objective To investigate the association between the plasminogen activator inhibitor-1 (PAI-1) 4G/ 5G gene polymorphism and the occurrence of myocardial and cerebrovascular infarctions in individuals from Tianjin, China. Methods The PAI-1 genotype was determined using allele-specific polymerase chain reaction (AS-PCR) in 56 myocardial infarction (Ml) patients, 54 cerebrovascular infarction(Cl) patients and 83 unrelated healthy controls. All subjects' clinical features and plasma PAI-1 activity levels were determined. Results The PAI-1 genotype distribution frequency of the single guanine deletion/insertion 4G/5G polymorphism (located -675 bp upstream from the start of transcription) significantly differed between the patients and healthy controls. In the MI group, the 4G/4G-genotype frequency was increased, but the 4G/5G-genotype is decreased when compared to the control group. In the Cl group, both the 4G/ 4G- and 4G/5G -genotypes occured at a lower frequency than those in the control group (P<0. 001) . The plasma PAI-1 activity level in the Ml group was lowered as the presence of the 4G allele decreases. In the Cl group, the frequency of 5G/5G was much higher than that of the control group (P<0. 001). The plasma PAI-1 activity level in the Cl group was elevated as the presence of the 5G allele increased. Furthermore, positive correlation between triglyceride, glucose levels and PAI-1 activity were found in all three groups (P<0. 001). Conclusions The PAI-1 4G/5G gene polymorphism is associated with a higher risk of Ml and Cl in individuals in Tianjin, China. The deletion/insertion polymorphism is probably an important hereditary risk factor for heart diseases. Moreover, triglyceride and glucose levels of plasma have functional importance in regulating PAI-1 activity.